Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS

About this update from Biomerica, Inc.

[{"type":"image","alt":"Biomerica, Inc.","displaySize":"","headline":null,"caption":"Biomerica, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":232,"height":39,"url":"https://media.zenfs.com/en/globenewswire.com/af40ff522792b4c3d1be4034218ddeca"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/m66J9gaNGHXIlBdKngBmxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTcxO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/af40ff522792b4c3d1be4034218ddeca","width":232,"height":39}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":148,"olType":false},{"type":"text","content":"IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical diagnostic solutions, is proud to announce that its inFoods® IBS diagnostic-guided therapy product is being featured in the Fall 2025 issue of Biotherapeutics Quarterly, a Henry Schein publication. The article, titled “Precision Medicine for IBS: A Novel, IBS-Specific Immune Response Guided Dietary Therapy”, presents comprehensive clinical and scientific insights into the company’s innovative approach to managing Irritable Bowel Syndrome (IBS).","length":568,"tagName":"p"},{"type":"text","content":"The publication details results from a randomized, multicenter, double-blind, placebo-controlled clinical trial evaluating the effectiveness of the inFoods® IBS test in identifying patient-specific dietary IBS triggers and guiding targeted food elimination to reduce IBS symptoms.","length":280,"tagName":"p"},{"type":"text","content":"Large Multicenter Study Demonstrates Clinically Meaningful Pain Reduction","length":73,"tagName":"p"},{"type":"text","content":"IBS affects an estimated 10% to 15% of adults in the United States and is known to significantly reduce quality of life and work productivity. Symptoms such as often severe abdominal pain, bloating, diarrhea, and constipation are frequently exacerbated by specific foods, yet identifying individual dietary triggers has historically relied on trial-and-error approaches.","length":370,"tagName":"p"},{"type":"text","content":"The inFoods IBS clinical trial an...

More updates from Biomerica, Inc.